Cg Oncology, Inc. · NASDAQ:CGON

Cg Oncology — Technical Presentation (November 2025)

7 slides from Cg Oncology's technical presentation, November 2025

  1. Slide 1: Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Unresponsive NMIBC with CIS

    Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Unresponsive NMIBC with CIS Sarah P. Psutka, MD, MSc, Sima P. Porten, MD, MPH, Kristen R. Scarpato, MD, MPH, Mary E. Westerman, MD, 1 2 3 4 Suzanne B. Merrill, MD, and Anne K. Schuckman, MD, 5 6 1 University of

  2. Slide 2: Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG

    Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin Sarah P. Psutka, MD, MSc; Sima P. Porten, MD, MPH; Kristen R. Scarpato, MD, MPH; Mary E. Westerman, MD; Suzanne B. Merrill, MD and Anne K. Schuckman,

  3. Slide 3: Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action

    Oncolytic Immunotherapy: 2 Chain Reaction of Cancer Cell Death: Cretostimogene Grenadenorepvec’s Viral progeny spread to additional Dual Mechanism of Action tumor cells Selectively Replicates in and 1 Lyses Bladder Cancer Cells Enters target cell Replicates in and lyses cancer cells Innate to Adapti

  4. Slide 4: BCG-Unresponsive Management per AUA/SUO Guidelines

    BCG-Unresponsive Management per AUA/SUO Guidelines 3 Sarah P. Psutka, MD, MSc

  5. Slide 5: Cretostimogene Grenadenorepvec Expanded Access Program in BCG-Unresponsive NMIBC with CIS

    4 Cretostimogene Grenadenorepvec Expanded Access Program in BCG-Unresponsive NMIBC with CIS Cretostimogene grenadenorepvec Co-Primary Endpoints: HR BCG-Unresponsive NMIBC Single-Arm, Open-Label, IVE Administration Safety & CR Anytime Real-World, Pragmatic, Diverse Population* Study Design / Regimen

  6. Slide 6: Treatment & Assessment Schedule

    5 Treatment & Assessment Schedule  Re-induction is permitted at Month 3 for non-responders*  Maintenance is every 3 months for year 1, every 6 months for year 2  Patients with partial response** may receive continued doses of cretostimogene at the discretion of the Investigator * Non-responders w

  7. Slide 7: Key Takeaways

    6 Key Takeaways • Oncolytic immunotherapy with dual MOA  Postulated innate to adaptive immune switching • Cretostimogene is a potentially effective, well tolerated, and durable regimen • Easily fits within existing clinic workflow • CRETO-EAP is actively enrolling patients with HR BCG-UR CIS +/- Ta

CG Oncology — Technical Presentation (November 2025) on 6ix